The Fort Worth Press - VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

USD -
AED 3.672503
AFN 62.499966
ALL 82.669181
AMD 376.230888
ANG 1.790083
AOA 916.999772
ARS 1397.329697
AUD 1.432203
AWG 1.80225
AZN 1.67023
BAM 1.684191
BBD 2.010067
BDT 122.460754
BGN 1.709309
BHD 0.377563
BIF 2964.056903
BMD 1
BND 1.276953
BOB 6.911428
BRL 5.234503
BSD 0.997972
BTN 93.511761
BWP 13.674625
BYN 2.954524
BYR 19600
BZD 2.007225
CAD 1.37869
CDF 2277.496692
CHF 0.78943
CLF 0.023245
CLP 917.860279
CNY 6.892701
CNH 6.899598
COP 3705.22
CRC 464.994123
CUC 1
CUP 26.5
CVE 94.953305
CZK 21.0509
DJF 177.721517
DKK 6.43958
DOP 59.786189
DZD 132.470985
EGP 52.607704
ERN 15
ETB 154.279108
EUR 0.861598
FJD 2.24025
FKP 0.747226
GBP 0.745845
GEL 2.704981
GGP 0.747226
GHS 10.903627
GIP 0.747226
GMD 73.511051
GNF 8747.24442
GTQ 7.642594
GYD 208.863457
HKD 7.82091
HNL 26.426305
HRK 6.490602
HTG 130.855608
HUF 335.350089
IDR 16900
ILS 3.11834
IMP 0.747226
INR 93.915798
IQD 1307.361768
IRR 1313025.000513
ISK 123.919958
JEP 0.747226
JMD 157.486621
JOD 0.709034
JPY 158.779501
KES 129.596279
KGS 87.448499
KHR 4005.063378
KMF 425.999732
KPW 900.014346
KRW 1499.150037
KWD 0.30629
KYD 0.831676
KZT 481.782876
LAK 21486.820464
LBP 89375.339068
LKR 313.699656
LRD 183.13807
LSL 17.013787
LTL 2.95274
LVL 0.60489
LYD 6.362944
MAD 9.303745
MDL 17.455028
MGA 4166.899883
MKD 53.064774
MMK 2100.167588
MNT 3569.46809
MOP 8.04266
MRU 39.802636
MUR 46.459758
MVR 15.459925
MWK 1730.481919
MXN 17.71475
MYR 3.958968
MZN 63.909906
NAD 17.013787
NGN 1377.430252
NIO 36.726715
NOK 9.699565
NPR 149.61272
NZD 1.71578
OMR 0.384501
PAB 0.997963
PEN 3.451997
PGK 4.309899
PHP 59.996501
PKR 278.8205
PLN 3.68025
PYG 6511.920293
QAR 3.639338
RON 4.389602
RSD 101.210987
RUB 80.756231
RWF 1459.995436
SAR 3.751761
SBD 8.041975
SCR 13.770102
SDG 601.000023
SEK 9.30298
SGD 1.27884
SHP 0.750259
SLE 24.600258
SLL 20969.510825
SOS 570.306681
SRD 37.339844
STD 20697.981008
STN 21.09741
SVC 8.732681
SYP 110.948257
SZL 17.012336
THB 32.628034
TJS 9.575933
TMT 3.51
TND 2.927264
TOP 2.40776
TRY 44.3539
TTD 6.780508
TWD 31.943014
TZS 2572.558996
UAH 43.82926
UGX 3737.239351
UYU 40.671515
UZS 12175.463071
VES 458.87816
VND 26350
VUV 119.508072
WST 2.738201
XAF 564.849586
XAG 0.013677
XAU 0.000219
XCD 2.70255
XCG 1.798634
XDR 0.702492
XOF 564.869043
XPF 102.697908
YER 238.59885
ZAR 16.865375
ZMK 9001.199211
ZMW 18.887324
ZWL 321.999592
  • RBGPF

    -13.5000

    69

    -19.57%

  • CMSC

    -0.0100

    22.87

    -0.04%

  • CMSD

    -0.1100

    22.63

    -0.49%

  • NGG

    0.2700

    82.33

    +0.33%

  • BCE

    0.0700

    25.83

    +0.27%

  • BTI

    -0.1600

    57.76

    -0.28%

  • RIO

    0.9300

    86.77

    +1.07%

  • GSK

    0.9600

    52.95

    +1.81%

  • RELX

    -1.3500

    32.46

    -4.16%

  • BP

    1.2200

    44.79

    +2.72%

  • RYCEF

    -0.2800

    15.69

    -1.78%

  • AZN

    1.7100

    185.78

    +0.92%

  • VOD

    0.1800

    14.66

    +1.23%

  • JRI

    0.1800

    11.86

    +1.52%

  • BCC

    1.6900

    73.57

    +2.3%

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street

Twelve months of national and global coverage to include long-form interviews, earned media, television commercials, iconic outdoor billboards, and accredited investor events

Text size:

NEW YORK CITY, NEW YORK / ACCESS Newswire / February 5, 2026 / Vivos Therapeutics, Inc. (NASDAQ:VVOS), a medical technology company focused on innovative solutions for breathing and sleep disorders, today announced that it has entered into a 12-part media series agreement with New to The Street, one of the longest-running business television and digital media platforms serving public companies in the U.S. and international markets.

The 12-month series is designed to expand Vivos Therapeutics' visibility among investors, healthcare professionals, and strategic partners through a comprehensive, multi-channel media strategy spanning linear television, digital platforms, social media, outdoor advertising, and live investor engagement.

As part of the agreement, Vivos Therapeutics will receive:

Long-form broadcast interviews distributed nationally and internationally

Earned media coverage supporting corporate milestones and clinical positioning

Television commercials airing as sponsored programming alongside New to The Street broadcasts

Iconic outdoor billboard placements in high-impact financial and metropolitan locations

Accredited investor events, providing direct engagement with screened, invitation-only investor audiences

The series will allow Vivos Therapeutics to consistently communicate its clinical progress, commercial execution, and long-term growth strategy throughout the year.

"Partnering with New to The Street provides a sustained, credible platform to communicate our story to a broad audience of investors and stakeholders," said a spokesperson for Vivos Therapeutics. "This multi-part series supports our commitment to education, transparency, and long-term shareholder engagement."

The first segment in the Vivos Therapeutics series is expected to begin airing in the coming weeks, with coverage continuing throughout the 12-month term.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ:VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment solutions for breathing and sleep disorders arising from certain dentofacial abnormalities, including obstructive sleep apnea (OSA) and snoring in adults and children.

Vivos' proprietary technologies have been cleared by the U.S. Food and Drug Administration (FDA) for use in adult patients diagnosed with all severity levels of OSA, as well as moderate-to-severe OSA in pediatric patients ages 6 to 17. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices represent the only FDA 510(k)-cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children.

OSA affects more than one billion people worldwide, with an estimated 80% or more remaining undiagnosed. Beyond disrupted sleep, OSA is closely linked to numerous serious chronic health conditions. While legacy treatments such as CPAP have addressed symptoms, they are often mechanistic and may not address the underlying anatomical causes of the disorder.

Founded in 2016 and headquartered in Littleton, Colorado, Vivos is working to transform the standard of care for sleep-disordered breathing through innovative technology, education, and strategic collaborations with sleep healthcare providers. The company's comprehensive approach-known as The Vivos Method-offers a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical solution, designed to address the root causes of OSA and improve long-term patient outcomes.

For more information, visit www.vivos.com.

About New to The Street

New to The Street is a 17-year-old, nationally and internationally syndicated business television brand that broadcasts weekly on Bloomberg Television as sponsored programming, featuring client interviews and television commercials. The program airs across the United States, MENA (Middle East & North Africa), and Latin America, delivering consistent global exposure.

In addition to its linear television distribution, New to The Street operates one of the largest YouTube subscriber channels in the financial and business media space, with over 4.4 million subscribers on New to The Street TV. The platform combines long-form interviews, earned media, digital amplification, and iconic outdoor advertising to deliver predictable, high-impact visibility for its clients.

https://youtube.com/@newtothestreettv

Media Contact:
Monica Brennan
New to The Street
[email protected]

SOURCE: New to The Street



View the original press release on ACCESS Newswire

G.Dominguez--TFWP